trending Market Intelligence /marketintelligence/en/news-insights/trending/J5OUIdT78iKK-02MaFVjUA2 content esgSubNav
In This List

Vertex Pharmaceuticals CFO steps down; interim named

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


Vertex Pharmaceuticals CFO steps down; interim named

Vertex Pharmaceuticals Inc. said Thomas Graney resigned as CFO of the company.

Graney will continue as an employee of the company and will help in the transition until February 2019.

Ian Smith, the company's executive vice president, COO and former CFO, will act as interim CFO.

Boston-based Vertex develops therapies for various diseases, including cystic fibrosis, beta-thalassemia and sickle cell disease.